BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 8996525)

  • 1. Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin.
    Fleming GF; O'Brien SM; Hoffman PC; Vokes EE; Vogelzang NJ; Schilsky RL; Waggoner SE; Ratain MJ
    Cancer Chemother Pharmacol; 1997; 39(3):227-32. PubMed ID: 8996525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
    Vokes EE; Haraf DJ; Drinkard LC; Hoffman PC; Ferguson MK; Vogelzang NJ; Watson S; Lane NJ; Golomb HM
    Cancer Chemother Pharmacol; 1995; 35(4):304-12. PubMed ID: 7530173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma.
    Ilson DH; Sirott M; Saltz L; Heelan R; Huang Y; Keresztes R; Kelsen DP
    Cancer; 1995 May; 75(9):2197-202. PubMed ID: 7712428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group.
    J Clin Oncol; 1995 Apr; 13(4):921-8. PubMed ID: 7707120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bimonthly high dose leucovorin and 5-fluorouracil 48-hour infusion with interferon-alpha-2a in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
    Tournigand C; Louvet C; de Gramont A; Lucchi E; Seitz JF; Mal F; Raymond E; Cady J; Carola E; Krulik M
    Cancer; 1997 Mar; 79(6):1094-9. PubMed ID: 9070485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I trial of 5-fluorouracil, leucovorin and interferon-alpha 2b administered by 24 h infusion in metastatic colorectal carcinoma.
    Cascinu S; Del Ferro E; Ligi M; Catalano G
    Anticancer Drugs; 1996 Jul; 7(5):520-4. PubMed ID: 8862717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
    Chen LT; Liu TW; Wu CW; Chung TR; Shiah HS; Jan CM; Liu JM; Whang-Peng J; Chang JY
    Oncology; 2002; 63(3):239-47. PubMed ID: 12381903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin, and cisplatin therapy in patients with advanced colorectal cancer.
    Scheithauer W; Depisch D; Kornek G; Pidlich J; Rosen H; Karall M; Prochaska M; Ernst A; Sebesta C; Eckhardt S
    Cancer; 1994 Mar; 73(6):1562-8. PubMed ID: 8156482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double modulation of 5-fluorouracil with interferon alpha 2a and high-dose leucovorin: a phase I and II study.
    Seymour MT; Johnson PW; Hall MR; Wrigley PF; Slevin ML
    Br J Cancer; 1994 Oct; 70(4):719-23. PubMed ID: 7917927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double modulation of 5-fluorouracil by high-dose leucovorin and interferon alpha 2b in advanced colorectal cancer: a phase I and a phase II study of weekly administration.
    Steger GG; Mader RM; Djavanmard MP; Gnant MF; Locker G; Marosi C; Rainer H; Jakesz R
    J Cancer Res Clin Oncol; 1994; 120(5):314-8. PubMed ID: 8126062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of recombinant human interferon alpha-2b combined with 5-fluorouracil and cisplatin in patients with advanced cancer.
    Trudeau M; Zukiwski A; Langleben A; Boos G; Batist G
    Cancer Chemother Pharmacol; 1995; 35(6):496-500. PubMed ID: 7882458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical trial of chemoimmunotherapy in combination with radiotherapy in stage IIIB cervical cancer patients.
    Wilailak S; Dangprasert S; Srisupundit S
    Int J Gynecol Cancer; 2003; 13(5):652-6. PubMed ID: 14675350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study.
    O'Dwyer PJ; Manola J; Valone FH; Ryan LM; Hines JD; Wadler S; Haller DG; Arbuck SG; Weiner LM; Mayer RJ; Benson AB
    J Clin Oncol; 2001 May; 19(9):2413-21. PubMed ID: 11331320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis.
    Vokes EE; Ratain MJ; Mick R; McEvilly JM; Haraf D; Kozloff M; Hamasaki V; Weichselbaum RR; Panje WR; Wenig B
    J Clin Oncol; 1993 Feb; 11(2):360-8. PubMed ID: 8426214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma.
    Chi KH; Chan WK; Shu CH; Law CK; Chen SY; Yen SH; Chen KY
    Cancer; 1995 Dec; 76(11):2186-92. PubMed ID: 8635020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trial of weekly intensive therapy with 5-fluorouracil on two different schedules combined with interferon alpha-2a and filgrastim in patients with advanced solid tumors: Eastern Cooperative Oncology Group Study P-Z991.
    Wadler S; Atkins M; Karp D; Neuberg D; Haynes H; Dutcher JP
    Cancer J Sci Am; 1998; 4(4):261-8. PubMed ID: 9689985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer. A Multicenter Phase II study.
    Punt CJ; Burghouts JT; Croles JJ; van Liessum PA; de Mulder PH; Kamm Y
    Cancer; 1993 Oct; 72(7):2107-11. PubMed ID: 8374869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I-II study of the addition of alpha-2a interferon to 5-fluorouracil/leucovorin. Pharmacokinetic interaction of alpha-2a interferon and leucovorin.
    Sinnige HA; Buter J; de Vries EG; Uges DR; Roenhorst HW; Verschueren RC; Sleijfer DT; Willemse PH; Mulder NH
    Eur J Cancer; 1993; 29A(12):1715-20. PubMed ID: 8398300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
    Gebbia V; Majello E; Testa A; Pezzella G; Giuseppe S; Giotta F; Riccardi F; Fortunato S; Colucci G; Gebbia N
    Cancer; 1996 Sep; 78(6):1300-7. PubMed ID: 8826954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.